LXRX 241220 0.50C (LXRX241220C500) Stock Options, News & Quotes

0.40
-0.05-11.11%

15min DelayClose Nov 22 16:00 ET

0.40High0.40Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Nov 22 06:49

Update

$Lexicon Pharmaceuticals (LXRX.US)$ Lexicon Pharmaceuticals Says Company Has Made Strategic Decision To Eliminate Its Commercial Operations And Rationalize Resources Across All Functions In Order To Preserve Cash And Focus Its Resources On Advancing Promising Clinical Development Pipeline Following Regulatory Update From FDA; Efforts Expected To Reduce 2025 Operating Costs By $100M
This decision follows the receipt of a "deficiencies preclude discussion" letter from the U.S. Food and Drug A...

105745367

Nov 20 09:08

$Lexicon Pharmaceuticals (LXRX.US)$ go up buy buy

105745367

Nov 19 12:59

$Lexicon Pharmaceuticals (LXRX.US)$ bounce back pls..

105745367

Nov 19 09:26

$Lexicon Pharmaceuticals (LXRX.US)$ go up pls

105745367

Nov 19 09:19

$Lexicon Pharmaceuticals (LXRX.US)$Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations Is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago